Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 10mg - lenalidomide (lenalidomide hydrochloride monohydrate) 10mg

Canada - English - Health Canada

natco pharma (canada) inc - lenalidomide - capsule - 10mg - lenalidomide 10mg - antineoplastic agents

Canada - English - Health Canada

apotex inc - lenalidomide - capsule - 10mg - lenalidomide 10mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - lenalidomide - capsule - 10mg - lenalidomide 10mg - antineoplastic agents

Canada - English - Health Canada

dr reddy's laboratories ltd - lenalidomide - capsule - 10mg - lenalidomide 10mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 10mg - capsule - 10 mg - active: lenalidomide 10mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf tartrazine titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - lenalidomide (unii: f0p408n6v4) (lenalidomide - unii:f0p408n6v4) - lenalidomide capsules in combination with dexamethasone are indicated for the treatment of adult patients with multiple myeloma (mm). lenalidomide capsules are indicated as maintenance therapy in adult patients with mm following autologous hematopoietic stem cell transplantation (auto-hsct). lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide capsules are indicated for the treatment of adult patients with mantle cell lymphoma (mcl) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.  lenalidomide capsules in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (fl).  lenalidomide capsules in combination with a rituximab product, is indicated for

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 2.5mg - lenalidomide (lenalidomide hydrochloride monohydrate) 2.5mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 5mg - lenalidomide (lenalidomide hydrochloride monohydrate) 5mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 15mg - lenalidomide (lenalidomide hydrochloride monohydrate) 15mg